Health
BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health
BASEL, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- BioVersys strengthens its Ansamycin Chemistry platform and research on tackling difficult-to-treat non-tuberculous mycobacteria (NTM) diseases.BioVersys joins forces with Hackensack Meridian Health (HMH) and their Center for Discovery and Innovation (CDI) to advance ansamycin antimicrobial candidates through an exclusive collaboration and license agreement.HMH is a leading US not-for-profit health care network, and the largest in New Jersey.
About this update from Bioversys Ag
[{"type":"image","alt":"BioVersys","displaySize":"","headline":null,"caption":"BioVersys","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vUEjL4Y7iwqZiGWE1EHKJQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkx/https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47","width":300,"height":65}},"lazy":false},{"type":"text","content":"BASEL, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) --","length":54,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"BioVersys strengthens its Ansamycin Chemistry platform and research on tackling difficult-to-treat non-tuberculous mycobacteria (NTM) diseases.","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"BioVersys joins forces with Hackensack Meridian Health (HMH) and their Center for Discovery and Innovation (CDI) to advance ansamycin antimicrobial candidates through an exclusive collaboration and license agreement.","length":216,"tagName":"p"}]},{"val":[{"type":"text","content":"HMH is a leading US not-for-profit health care network, and the largest in New Jersey. ","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"NTMs are ubiquitous environmental bacteria, predominately causing morbidity and death in those with long-term lung conditions, like bronchiectasis or cystic fibrosis and requiring long-term antibiotic combination treatments.","length":239,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":684,"olType":false},{"type":"text","content":"BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today, that it has entered into an exclusive ansamycin drug discovery collaboration and license agreement with Hackensack Meridian Health (HMH), the parties will jointly profile and develop ansamycin candidates coming from HMH. HMH is eligible to receive an upfront and near-term payments as well as royalties on future sales.","length":574,"tagName":"p"},{"type":"text","content":"BioVersys’ proprietary Ansamycin Chemistry platform has been developed through our research teams ...